Company news
Halozyme Therapeutics, Inc. news in 2020
Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
November 22, 2020
Halozyme Raises Full Year 2020 Guidance
November 22, 2020
Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference
November 17, 2020
Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Positive Breast Cancer
November 12, 2020
Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE®
November 4, 2020
Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance
November 1, 2020
Halozyme To Host THIRD Quarter 2020 Financial Results webcast and Conference Call
October 21, 2020
Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology
October 5, 2020
Halozyme Announces Poster Presentation Of Data From Roche's Phase 1b Study Evaluating Atezolizumab For Subcutaneous Administration Utilizing Enhanze® In Non-Small Cell Lung Cancer
September 16, 2020
Halozyme Announces Janssen Submission For FDA Approval Of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) For The Treatment Of Patients With Light Chain (AL) Amyloidosis
September 9, 2020
Halozyme To Present At Upcoming Virtual Investor Conferences
September 8, 2020
Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference
September 1, 2020
Halozyme Reports Significant Recent Achievements And Second Quarter 2020 Results
August 9, 2020
Halozyme To Present At Canaccord Genuity 40th Annual Growth Conference
August 3, 2020
Halozyme To Host Second Quarter 2020 Financial Results Webcast And Conference Call
July 28, 2020
Halozyme Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer
June 28, 2020
Halozyme To Receive $10 Million Milestone Payment From Janssen
June 21, 2020
Halozyme To Participate In The BMO 2020 Prescriptions For Success Healthcare Conference
June 16, 2020
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress
June 12, 2020
Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
June 3, 2020
Halozyme To Receive $15 Million Milestone Payment From Janssen
May 13, 2020
Halozyme Reports First Quarter 2020 Results
May 10, 2020
Halozyme To Present At The Bank Of America Securities 2020 Healthcare Conference
May 6, 2020
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO™ Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
April 30, 2020
Halozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX® Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
April 29, 2020
Halozyme To Host First Quarter 2020 Financial Results Webcast and Conference Call
April 27, 2020
Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
April 25, 2020
Halozyme Announces Change Of Location Of Annual Stockholders' Meeting
April 2, 2020
Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference
February 25, 2020
Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology
February 24, 2020
Halozyme Reports Fourth Quarter and Full Year 2019 Results
February 23, 2020
Halozyme Announces CFO Transition
February 23, 2020
Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call
February 9, 2020
Halozyme Provides 2020 Business Update And Financial Guidance
January 13, 2020
Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference
January 2, 2020
Calls in 2020
Decks in 2020
- Q3 2020 Earnings Presentation
Earnings · 12 slides · Nov 2, 2020
- Q2 2020 Earnings Presentation
Earnings · 13 slides · Aug 10, 2020
- 38th Annual J.P. Morgan Healthcare Conference (January 2020)
Conference · 22 slides · Jan 16, 2020